The HYBRID study: Efficacy and safety of HYbrid argon plasma coagulation technique in patients with Barrett's esophagus-Related dysplasia: a multicenter Italian prospective stuDy

Aims Hybrid argon plasma coagulation (H-APC) is a novel technique for the ablation of neoplastic BE, consisting in submucosal fluid injection and subsequent APC of visible BE. Aim of this study was to assess H-APC efficacy, safety and tolerability.

Methods We prospectively included patients undergoing H-APC at 4 ItalianHospitals (Sept. 2022- March 2024).

Patients with BE C3M5 maximum extent, low- or high-grade dysplasia(LD, HGD) or residual BE after endoscopic resection (ER) of visiblelesions were included. Patients who had undergone previous ablative treatments were excluded.

The primary endpoints were complete eradication of intestinalmetaplasia (CE-IM) and dysplasia (CE-D).

The secondary endpoints were safety in terms of major and minor adverse events (AEs) and tolerability, assessed using pain (0-10) and dysphagia (0-5) scores within 7 days post-ablation (NCT05645679).

Results Among the 51 enrolled patients (mean C 0.43 cm (SD 0.72), mean M 2.20 cm (SD 1.09)) who completed the treatment (80 H-APC sessions), 45.1% (23/51) had prior ER of visible lesions. All patients achieved both CE-IM and CE-D (51/51), requiring a mean of 1.51 (SD 0.83) sessions.

Only one case of fever and absolute dysphagia was observed, 1/51 (1,96%) AEs. Regarding tolerability, mean pain score was 1.3 (SD 1.99) while mean dysphagia score was 1.28 (SD 0.56).

Conclusions The H-APC technique showed promising results in terms of effectiveness and safety with a good tolerability in achieving initial CE-IM and CE-D in a selected population of BE patients.

Publikationsverlauf

Artikel online veröffentlicht:
27. März 2025